A longtime accomplished specialist with significant expertise in the biotechnology and pharmaceutical industries, JeanMarie Guenot is at this time working to develop innovative autoimmune therapies for the treatment of cancer. Newson6 covered her work in their piece “Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies” found here.
With her more than 20 years experience, as noted on her biography page at Guenot LLC, JeanMarie Guenot has worked with all phases of companies from research and development to corporate and business-related expansion as well as venture capital. She initially trained in physical and medicinal chemistry with a focus on protein structure prediction, X-ray and NMR refinement and drug design.
Prior to her current role as president and chief executive at San Francisco-based Amphivena Therapeutics, Guenot founded a start-up ophthalmic company, SKS Ocular, which focused on developing ocular drug delivery technologies and therapeutics for glaucoma and ocular inflammation.
She held a variety of positions that included business advisor for Hoffmann-La Roche in Shanghai, China and Basel, Switzerland; vice president of corporate and business development at PDL BioPharma and managing venture capital investments at Atlas Venture where she was also took part in building life science companies.
JeanMarie Guenot received her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.
Making use of Jeanmarie Guenot’s education and building on her broad experience, Amphivena Therapeutics is working to eliminate blood cancers by cultivating therapies that adjust to a patient’s immune system.
Last year, Amphivena Therapeutics made it known that the US Food and Drug Administration (FDA) has acknowledged and accepted an investigational new drug application for AMV564, the company’s lead drug candidate.
Guenot commented in a statement that the acceptance of the first clinical trial of AMV564 symbolizes a crucial advancement effort for the company to produce a necessary therapeutic alternative for acute myeloid leukemia (AML) patients and their medical doctors.
She added Amphivena Therapeutics anticipates beginning its AMV564 clinical development program and weighing the impending possibilities for patients. Read more about JeanMarie’s partnership with Takeda on their website.